|
|
|
| Clinical effect of Yiqi Fumai Injection combined with statins in the treatment of chronic heart failure complicated with atrial fibrillation |
| SU Haiyan1 WANG Kelong2 |
1.Department of Geriatrics, No.215 Hospital of Shaanxi Nuclear Industry, Shaanxi Province, Xianyang 712000, China;
2.Department of Cardiology, the First Affiliated Hospital of Xi′an Jiaotong University, Shaanxi Province, Xi′an 710000, China |
|
|
|
Abstract Objective To investigate the clinical effect of Yiqi Fumai Injection combined with statins in the treatment of chronic heart failure (CHF) with atrial fibrillation. Methods A total of 103 patients with CHF and atrial fibrillation who were admitted to the No.215 Hospital of Shaanxi Nuclear Industry from January 2016 to December 2017 were divided into the control group (n = 51) and the observation group (n = 52) by random number table method. The control group was given Rosuvastatin on the basis of conventional treatment, and the observation group was given Yiqi Fumai Injection on the basis of the control group. N-terminal B-brain natriuretic peptide (NT-proBNP) level, 6-min walking distance (6MWT), left ventricular end-diastolic diameter (LVEDd), left ventricular short-axis shortening rate (LVFS), left ventricle were observed before and after treatment. The recurrence rate of paroxysmal atrial fibrillation, the incidence of permanent atrial fibrillation and clinical efficacy were calculated. Results Compared with before treatment, the levels of 6MWT, LVFS and LVEF in the two groups were significantly increased after treatment (P < 0.05), and the observation group was significantly higher than the control group (P < 0.05). The levels of NT-proBNP and LVEDd in the two groups after treatment were significantly lower than those before treatment (P < 0.05), and the observation group was significantly lower than the control group (P < 0.05). The recurrence rate of atrial fibrillation and the rate of conversion to permanent atrial fibrillation in the observation group were significantly lower than those in the control group (P < 0.05). The clinical effective rate in the observation group was higher than that in the control group, and the difference was statistically significant (P < 0.05). Conclusion Yiqi Fumai Injection combined with Rosuvastatin can reduce NT-proBNP levels in patients with CHF complicated with atrial fibrillation, improve cardiac function, and effectively control ventricular rate, which is worthy of clinical promotion and application.
|
|
|
|
|
|
[1] 赵明昕，于霞，张晓非，等.瑞舒伐他汀钙片联合芪参益气滴丸治疗慢性心力衰竭的临床观察[J].中国药房，2017，28（8）：1098-1101.
[2] 郑委.瑞舒伐他汀治疗老年慢性心力衰竭合并房颤的疗效观察[J].临床医药文献杂志，2015，2（17）：3499.
[3] 王文君.瑞舒伐他汀治疗老年慢性心力衰竭合并房颤患者的效果观察[J].心血管病防治知识，2016（2）：53-54.
[4] 翟小菊，惠学志.益气复脉注射液治疗心力衰竭临床疗效观察[J].中西医结合心脑血管病杂志，2011，9（8）：899-900.
[5] 黄峻，杨杰孚.遵循新指南规范心力衰竭防治工作[J].中华心血管病杂志，2014，42（2）：91-93.
[6] 马长生，姚艳.2011年ACCF/AHA/HRS心房颤动防治指南解读[J].心血管病学进展，2011，32（4）：487-490.
[7] 郑筱萸.中药新药临床研究指导原则（试行）[M].北京：中国医药科技出版社，2002：77-85.
[8] 周茂松，孙晓玫，李莉.运动疗法对老年慢性左心室射血保留的心力衰竭患者的疗效研究[J].河北医学，2018，24（3）：419-422.
[9] 吴焱贤，黄裕立，陈玉映，等.血浆NT-proBNP与急性非ST段抬高型心肌梗死患者冠脉病变的相关性研究[J].实用医学杂志，2013，29（13）：2135-2137.
[10] 潘桂俊，王惠华，唐慧芸，等.专科-全科联合团队模式下慢性心力衰竭患者的社区管理研究[J].中华全科医学，2016，14（9）：1522-1524，1588.
[11] 吴娜，周瑛，李娟，等.老年慢性心力衰竭患者心脏事件与外周血Adropin水平的相关性及其临床意义[J].心脏杂志，2018，30（4）：446-448，457.
[12] Jones JD，Khand AU，Douglas H，et al. The intersection of artrial fibrillation and heart failure in a hospitalized population [J]. Acta Cardiol，2013，68（4）：395-402.
[13] 刘蕾，张煜，董丽露，等.老年心力衰竭合并慢性房颤的药物治疗[J].中国老年学杂志，2015，35（8）：2293-2296.
[14] 胡岚.琥珀酸美托洛尔缓释片联合瑞舒伐他汀钙治疗慢性心力衰竭60例疗效分析[J].中国医药科学，2017，7（20）：60-62.
[15] 刘英，刘惠亮.阿托伐他汀多效性研究进展[J].中国全科医学，2013，16（6）：601-604.
[16] 穆金兴，陈要起，陈洪波，等.阿托伐他汀与瑞舒伐他汀对老年高血压患者颈动脉内膜中层厚度及血清ⅡA型分泌型磷脂酶A2水平的影响比较[J].中国医药，2017， 12（5）：724-727.
[17] 高艳丽，张宝奇，刘玉才，等.瑞舒伐他汀与阿托伐他汀对老年冠状动脉粥样硬化性心脏病患者抑郁症状的疗效比较[J].中国医药，2017，12（5）：673-676.
[18] 梁海雁，骈晶，姚传臣.瑞舒伐他汀对阵发性房颤患者C-反应蛋白、左心房内径及房颤复发率的影响[J].河北医药，2012，34（19）：2907-2908.
[19] 刘英芹，李继福.瑞舒伐他汀治疗老年慢性心力衰竭合并房颤患者效果观察[J].山东医药，2014，54（42）：42-44.
[20] 郑委.瑞舒伐他汀治疗老年慢性心力衰竭合并房颤的疗效观察[J].临床医药文献杂志，2015，2（17）：3499.
[21] 张光明.观察瑞舒伐他汀治疗老年慢性心力衰竭合并房颤患者的效果[J].中西医结合心血管病杂志，2016，4（16）：68，70.
[22] 唐荣江，秦立，何秀云.瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效对比研究[J].中国医药科学，2017，7（19）：74-76.
[23] 靳文学，乔秀兰，何德英.益气复脉汤治疗慢性心衰的临床观察[J].中国中医急症，2015，24（12）：2211-2213.
[24] 杨昌林.注射用益气复脉（冻干）治疗老年冠心病慢性心力衰竭临床研究[J].实用老年医学，2014，28（7）：607-608.
[25] 安丽丽，张新梅，黄文正，等.注射用益气复脉联合重组人脑钠肽治疗老年冠心病慢性心力衰竭急性加重期效果观察[J].中国医学创新，2017，14（5）：85-88.
[26] 王贤良，马宁，侯雅竹，等.注射用益气复脉（冻干）联合西药常规治疗慢性心力衰竭疗效的Meta分析[J].中医杂志，2016，57（5）：391-395.
[27] 黄健雄，刘晓凯，郑伟峰.贝那普利联合阿托伐他汀对慢性心力衰竭的治疗效果及对血浆NT-proBNP水平的影响[J].中国生化药物杂志，2017，37（1）：245-247.
[28] 张奇志，赖胜华，王娟，等.NT-pro-BNP与hs-CRP在慢性心力衰竭危险预测中的应用价值分析[J].中国医药科学，2016，6（18）：185-187.
[29] 何文芳，杨新春.NT-proBNP和6MWT对曲美他嗪治疗慢性心力衰竭的疗效评估及其相关性研究[J].湖南中医药大学学报，2014，34（7）：44-46，58. |
|
|
|
